Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) often induces chronic osteomyelitis and then bone defects. Here, gentamicin-loaded silk/nanosilver composite scaffolds were developed to treat MRSA-induced chronic osteomyelitis. AgNO3 was reduced with silk as a reducing agent in formic acid, forming silver nanoparticles in situ that were distributed uniformly in the composite scaffolds. Superior antibacterial properties against MRSA were achieved for the composite scaffolds, without the compromise of osteogenesis capacity. Then gentamicin was loaded on the scaffolds for better treatment of osteomyelitis. In vivo results showed effective inhibition of the growth of MRSA bacteria, confirming the promising future in the treatment of chronic osteomyelitis.
Highlights
IntroductionA serious clinical disease, usually results in substantial disability
Chronic osteomyelitis, a serious clinical disease, usually results in substantial disability
Small AgNPs clusters appeared occasionally in the scaffolds with Ag concentration of 0.5% and 1%, the EDS spectra indicated the homogeneous distribution of Ag element inside the scaffolds
Summary
A serious clinical disease, usually results in substantial disability. The abuse of antibiotics and cross infection in hospital aggravated the occurrence of chronic osteomyelitis. The most common resistant strains are methicillin-resistant Staphylococcus aureus (MRSA).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
